|
gptkbp:instanceOf
|
gptkb:chemical_compound
recreational drug
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:bannedIn
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:New_Zealand
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:CASNumber
|
2759-28-6
|
|
gptkbp:category
|
gptkb:piperazines
designer drugs
|
|
gptkbp:chemicalFormula
|
C11H16N2
|
|
gptkbp:discoveredBy
|
1944
|
|
gptkbp:drugClass
|
stimulant
|
|
gptkbp:effect
|
increased energy
euphoria
stimulant
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
gptkb:Wellcome_Research_Laboratories
|
|
gptkbp:hasInChIKey
|
InChI=1S/C11H16N2/c1-2-6-11(7-3-1)10-13-8-4-12-5-9-13/h1-3,6-7,12H,4-5,8-10H2
|
|
gptkbp:hasSMILES
|
c1ccc(cc1)CN2CCNCC2
|
|
gptkbp:hasStreet
|
gptkb:Legal_E
gptkb:A2
gptkb:BZP
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
benzylpiperazine
|
|
gptkbp:IUPACName
|
gptkb:1-benzylpiperazine
|
|
gptkbp:legalStatus
|
illegal in many countries
Schedule I controlled substance in the United States
Class C drug in the United Kingdom
|
|
gptkbp:mechanismOfAction
|
serotonin-norepinephrine-dopamine releasing agent
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
176.26 g/mol
|
|
gptkbp:PubChem_CID
|
6927
7197
CHEMBL2104666
|
|
gptkbp:relatedTo
|
gptkb:TFMPP
gptkb:mCPP
trifluoromethylphenylpiperazine
|
|
gptkbp:routeOfAdministration
|
oral
insufflation
|
|
gptkbp:sideEffect
|
nausea
anxiety
headache
insomnia
|
|
gptkbp:toxicity
|
can cause seizures at high doses
|
|
gptkbp:UNII
|
6G7Y47VG1H
|
|
gptkbp:used_in
|
party pills
|
|
gptkbp:usedFor
|
recreational drug
chemical intermediate
|
|
gptkbp:bfsParent
|
gptkb:1-benzylpiperazine
|
|
gptkbp:bfsLayer
|
8
|